Recent advances in the research and development of B-Raf inhibitors

Current Medicinal Chemistry

Volumn 17, Issue 16, 2010, Pages 1618-1634

  Li, Hui Fang ^a   Chen, Yadong ^a   Rao, Sha Sha ^b   Chen, Xiu Mei ^a   Liu, Hai Chun ^a   Qin, Ji Hong ^c   Tang, Wei Fang ^a   Yue Wang, ^a   Zhou, Xiang ^a   Lu, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c Shanghai Haitian Pharmaceutical Science Development Co LTD   (China)

Author keywords

B raf; B raf kinase inhibitors; B rafv600; Binding mode; Mechanism of action; Sar

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; 2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; AAL 881; B RAF KINASE; B RAF KINASE INHIBITOR; BENZIMIDAZOLE DERIVATIVE; CHIR 265; CS 240; CS 292; ENZYME INHIBITOR; GSK 2118436; IMIDAZOLE DERIVATIVE; L 779450; LBT 613; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PLX 3202; PLX 4032; PLX 4720; PURINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAF PROTEIN; RAS PROTEIN; RO 5185426; SB 699393; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 281;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; MOLECULAR DOCKING; NONHUMAN; STRUCTURE ACTIVITY RELATION; THYROID CANCER;

ANIMALS; DRUG DISCOVERY; HUMANS; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 77953518540     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791111242     Document Type: Article

References (90)

1. Malumbres, M.; Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer, 2003, 3, 459-465.
2. Howe, L.R.; Leevers, S.J.; Gomez, N.; Nakielny, S.; Cohen, P.; Marshall, C.J. Activation of the MAP kinase pathway by the protein kinase raf. Cell, 1992, 71, 335-342.
3. Moodie, S.A.; Willumsen, B.M.; Weber, M.J.; Wolfman, A. Complexes of RA GTP with Raf-1 and Mitogen-activated Protein Kinase Kinase. Science, 1993, 260, 1658-1661.
4. Vojtek, A.B.; Hollenberg, S.M.; Cooper, J.A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell, 1993, 74, 205-214.
5. Chong, H.; Vikis, H.G.; Guan, K.L. Mechanisms of regulating the Raf kinase family. Cell Signal., 2003, 15, 463-469
6. Yang, S.H.; Sharrocks, A.D.; Whitmarsh, A.J. Transcriptional regulation by the MAP kinase signaling cascades. Gene, 2003, 320, 3-21.
7. Gorden, A.; Osman, I.; Gai, W.M.; He, D.; Huang, W.Q.; Davidson, A.; Houghton, A.N.; Busam, K.; Polsky, D. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res., 2003, 63, 3955-3957.
8. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, N.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R. Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A. Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.C.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Siegler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R. Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.
9. Brose, M.S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I. Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A. Roth, J.A.; Albelda, S.M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P.A.; Wooster, R.; Stratton, M.R.; Weber, B.L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 2002, 62, 6997-7000.
10. Mercer, K.E.; Pritchard, C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta. Rev. Cancer, 2003, 1653, 25-40.
11. Sebolt-Leopold, J.S. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin. Cancer Res., 2008, 14, 3651-3656.
12. Wellbrock, C.; Karasarides, M.; Marais, R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol., 2004, 5, 875-885.
13. Beeram, M.; Patnaik, A.; Rowinsky, E.K. Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol., 2005, 23, 6771-6790.
14. Sridhar, S.S.; Hedley, D.; Siu, L.L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther., 2005, 4, 677-685.
15. Drugan, J.K.; KhosraviFar, R.; White, M.A.; Der, C.J.; Sung, Y.J. Hwang, Y.W.; Campbell, S.L. Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation. J. Biol. Chem., 1996, 271, 233-237.
16. Rapp, U.R.; Goldsborough, M.D.; Mark, G.E.; Bonner, T.I.; Groffen, J.; Reynolds, F.H.; Jr.; Stephenson, J.R. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. U.S.A., 1983, 80, 4218-4222.
17. Emuss, V.; Garnett, M.; Mason, C.; Marais, R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res., 2005, 65, 9719-9726.
18. Wan, P.T.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D. Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116, 855-867.
19. Garnett, M.J.; Rana, S.; Paterson, H.; Barford, D.; Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell, 2005, 20, 963-969.
20. Rushworth, L.K.; Hindley, A.D.; O'Neill, E.; Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell Biol., 2006, 26, 2262-2272.
21. Hocker, T.; Tsao, H.S. Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants. Hum. Mutat., 2007, 28, 578-588.
22. Xu, X.L.; Quiros, R.M.; Gattuso, P.; Ain, K.B.; Prinz, R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res., 2003, 63, 4561-4567.
23. Fransen, K.; Klintenas, M.; Osterstrom, A.; Dimberg, J.; Monstein, H.J.; Soderkvist, P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis, 2004, 25, 527-533.
24. Dibb, N.J.; Dilworth, S.M.; Mol, C.D. Opinion Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer, 2004, 4, 718-727.
25. Avruch, J.; Khokhlatchev, A.; Kyriakis, J.M.; Luo, Z.; Tzivion, G. Vavvas, D.; Zhang, X.F. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res., 2001, 127-155.
26. Rajakulendran, T.; Sahmi, M.; Lefrancois, M.; Sicheri, F.; Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature, 2009, 461, 542-545.
27. Weber, C.K.; Slupsky, J.R.; Kalmes, H.A.; Rapp, U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res., 2001, 61, 3595-3598.
28. Karreth, F.A.; DeNicola, G.M.; Winter, S.P.; Tuveson, D.A. C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E. Mol. Cell, 2009, 36, 477-486.
29. King, A.J.; Patrick, D.R.; Batorsky, R.S.; Ho, M.L.; Do, H.T. Zhang, S.Y.; Kumar, R.; Rusnak, D.W.; Takle, A.K.; Wilson, D.M.; Hugger, E.; Wang, L.; Karreth, F.; Lougheed, J.C.; Lee, J. Chau, D.; Stout, T.J.; May, E.W.; Rominger, C.M.; Schaber, M.D. Luo, L.; Lakdawala, A.S.; Adams, J.L.; Contractor, R.G.; Smalley, K.S.; Herlyn, M.; Morrissey, M.M.; Tuveson, D.A.; Huang, P.S. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res., 2006, 66, 11100-11105.
30. Tsai, J.; Lee, J.T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S. Bremer, R.; Gillette, S.; Kong, J.; Haass, N.K.; Sproesser, K.; Li, L.; Smalley, K.S.; Fong, D.; Zhu, Y.L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.H.; Schlessinger, J.; Zhang, K.Y.; West, B.L.; Powell, B.; Habets, G.; Zhang, C. Ibrahim, P.N.; Hirth, P.; Artis, D.R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 3041-3046.
31. Hansen, J.D.; Grina, J.; Newhouse, B.; Welch, M.; Topalov, G. Littman, N.; Callejo, M.; Gloor, S.; Martinson, M.; Laird, E. Brandhuber, B. J.; Vigers, G.; Morales, T.; Woessner, R. Randolph, N.; Lyssikatos, J.; Olivero, A. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett., 2008, 18, 4692-4695.
32. Berger, D.M.; Torres, N.; Dutia, M.; Powell, D.; Ciszewski, G. Gopalsamy, A.; Levin, J.I.; Kim, K.-H.; Xu, W.; Wilhelm, J.; Hu, Y.; Collins, K.; Feldberg, L.; Kim, S.; Frommer, E.; Wojciechowicz, D.; Mallon, R. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 6519-6523.
33. Smith, A.L.; Demorin, F.F.; Paras, N.A.; Huang, Q.; Petkus, J.K. Doherty, E.M.; Nixey, T.; Kim, J.L.; Whittington, D.A.; Epstein, L.F.; Lee, M.R.; Rose, M.J.; Babij, C.; Fernando, M.; Hess, K.; Le, Q.; Beltran, P.; Carnahan, J. Selective inhibitors of the mutant Braf pathway: discovery of a potent and orally bioavailable aminoisoquinoline. J. Med. Chem., 2009, 52, 6189-6192.
34. Michaloglou, C.; Vredeveld, LCW.; Mooi, W.J.; Peeper, D.S. BRAF(E600) in benign and malignant human tumours. Oncogene, 2008, 27, 877-895.
35. Zhang, B.H.; Guan, K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J., 2000, 19, 5429-5439.
36. Bollag, G.; Freeman, S.; Lyons, J.F.; Post, L.E. Raf pathway inhibitors in oncology. Curr. Opin. Investig. Drugs, 2003, 4, 1436-1441.
37. Strumberg, D.; Seeber, S. Raf kinase inhibitors in oncology. Onkologie, 2005, 28, 101-107.
38. Smith, R.A.; Dumas, J.; Adnane, L.; Wilhelm, S.M. Recent advances in the research and development of RAF kinase inhibitors. Curr. Top. Med. Chem., 2006, 6, 1071-1089.
39. Lackey, K.; Cory, M.; Davis, R.; Frye, S.V.; Harris, P.A.; Hunter, R.N.; Jung, D.K.; McDonald, O.B.; McNutt, R.W.; Peel, M.R. Rutkowske, R.D.; Veal, J.M.; Wood, E.R. The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 223-226.
40. Lowinger, T.B.; Riedl, B.; Wood, J.; Dumas, J.; Smith, R.A. Khire, U.; Bankston, D.; Monahan, M.K.; Scott, W.J.; Lee, W. Johnson, J.S.; Caringal, Y.; Turner, T.; Gane, T.; Kennure, N. Barbosa, J. Discovery of a novel class of potent Raf kinase inhibitors: Structure activity relationships. Clin. Cancer Res., 2000, 6, 335.
41. Lyons, J.F.; Wilhelm, S.; Hibner, B.; Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer, 2001, 8, 219-225.
42. Smith, R.A.; Barbosa, J.; Blum, C.L.; Bobko, M.A.; Caringal, Y.V.; Dally, R.; Johnson, J.S.; Katz, M.E.; Kennure, N.; Kingery-Wood, J.; Lee, W.; Lowinger, T.B.; Lyons, J.; Marsh, V.; Rogers, D.H.; Swartz, S.; Walling, T.; Wild, H. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: Identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett., 2001, 11, 2775-2778.
43. Lowinger, T.B.; Riedl, B.; Dumas, J.; Smith, R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des., 2002, 8, 2269-2278.
44. Khire, U.R.; Bankston, D.; Barbosa, J.; Brittelli, D.R.; Caringal, Y. Carlson, R.; Dumas, J.; Gane, T.; Heald, S. L.; Hibner, B.; Johnson, J. S.; Katz, M.E.; Kennure, N.; Kingery-Wood, J.; Lee, W.; Liu, X.G.; Lowinger, T.B.; McAlexander, I.; Monahan, M.K.; Natero, R.; Renick, J.; Riedl, B.; Rong, H.; Sibley, R.N.; Smith, R.A.; Wolanin, D. Omega-carboxypyridyl substituted ureas as Raf kinase in-hibitors: SAR of the amide substituent. Bioorg. Med. Chem. Lett., 2004, 14, 783-786.
45. McDonald, O.; Lackey, K.; Davis-Ward, R.; Wood, E.; Samano, V.; Maloney, P.; Deanda F.; Hunter, R. Aza-stilbenes as potent and selective c-RAF inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5378-5383.
46. Li, H.F.; Lu, T.; Zhu, T.; Jiang, Y.J.; Rao, S.S.; Hu, L.Y.; Xin, B.T.; Chen, Y.D. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas. Eur. J. Med. Chem., 2009, 44, 1240-1249.
47. Niculescu-Duvaz, I.; Roman, E.; Whittaker, S.R.; Friedlos, F. Kirk, R.; Scanlon, I.J.; Davies, L.C.; Niculescu-Duvaz, D.; Marais, R.; Springer, C.J. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. J. Med. Chem., 2008, 51, 3261-3274.
48. Takle, A.K.; Brown, M.J.; Davies, S.; Dean, D.K.; Francis, G. Gaiba, A.; Hird, A.W.; King, F.D.; Lovell, P.J.; Naylor, A.; Reith, A.D.; Steadman, J.G.; Wilson, D.M. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett., 2006, 16, 378-381.
49. Takle, A.K.; Bamford, M.J.; Davies, S.; Davis, R.P.; Dean, D.K. Gaiba, A.; Irving, E.A.; King, F.D.; Naylor, A.; Parr, C.A.; Ray, A.M.; Reith, A.D.; Smith, B.B.; Staton, P.C.; Steadman, J.G. Stean, T.O.; Wilson, D.M. The Identification of Potent, Selective and CNS penetrant Furan-based Inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett., 2008, 18, 4373-4376.
50. Luo, C.; Xie, P.; Marmorstein, R. Identification of BRAF inhibitors through in silico screening. J. Med. Chem., 2008, 51, 6121-6127.
51. Tang, J.; Hamajima, T.; Nakano, M.; Sato, H.; Dickerson, S.H. Lackey, K.E. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4610-4614.
52. Ramurthy, S.; Subramanian, S.; Aikawa, M.; Amiri, P.; Costales, A.; Dove, J.; Fong, S.; Jansen, J.M.; Levine, B.; Ma, S.; McBride, C.M.; Michaelian, J.; Pick, T.; Poon, D.J.; Girish, S.; Shafer, C.M. Stuart, D.; Sung, L.; Renhowe, P.A. Design and synthesis of orally bioavailable benzimidazoles as raf kinase inhibitors. Bioorg. Med. Chem. Lett., 2008, 51, 7049-7052.
53. Wolin, R.L.; Bembenek, S.D.; Wei, J.; Crawford, S.; Lundeen, K. Brunmark, A.; Karlsson, L.; Edwards, J.P.; Blevitt, J.M. Dual binding site inhibitors of B-RAF kinase. Bioorg. Med. Chem. Lett., 2008, 18, 2825-2829.
54. Gopalsamy, A.; Ciszewski, G.; Hu, Y.; Lee, F.; Feldberg, L. Frommer, E.; Kim, S.; Collins, K.; Wojciechowicz, D.; Mallon, R. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 2735-2738.
55. Lyne, P.D.; Aquila, B.; Cook, D.J.; Dakin, L.A.; Ezhuthachan, J. Ioannidis, S.; Pontz, T.; Su, M.; Ye, Q.; Zheng, X.L.; Block, M.H. Cowen, S.; Deegan, T.L.; Lee, J.W.; Scott, D.A.; Custeau, D. Drew, L.; Poondru, S.; Shen, M.H.; Wu, A. Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity. Bioorg. Med. Chem. Lett., 2009, 19, 1026-1029.
56. Niculescu-Duvaz, D.; Gaulon, C.; Dijkstra, H.P.; Niculescu-Duvaz, I.; Zambon, A.; Menard, D.; Suijkerbuijk, B.M.; Nourry, A.; Davies, L.; Manne, H.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Whittaker, S.; Kirk, R.; Gill, A.; Taylor, R.D.; Raynaud, F.I.; Moreno-Farre, J.; Marais, R.; Springer, C.J. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J. Med. Chem., 2009, 52, 2255-2264.
57. Xie, P.; Streu, C.; Qin, J.; Bregman, H.; Pagano, N.; Meggers, E.; Marmorstein, R. The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF Kinase. Biochemistry, 2009, 48, 5187-5198.
58. Menard, D.; Niculescu-Duvaz, I.; Dijkstra, H.P.; Niculescu-Duvaz, D.; Suijkerbuijk, B.M.; Zambon, A.; Nourry, A.; Roman, E.; Davies, L.; Manne, H.A.; Friedlos, F.; Kirk, R.; Whittaker, S.; Gill, A.; Taylor, R.D.; Marais, R.; Springer, C.J. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. J. Med. Chem., 2009, 52, 3881-3891.
59. Niculescu-Duvaz, I.; Roman, E.; Whittaker, S. R.; Friedlos, F. Kirk, R.; Scanlon, I.J.; Davies, L.C.; Niculescu-Duvaz, D.; Marais, R.; Springer, C.J. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J. Med. Chem., 2006, 49, 407-416.
60. Wong, K.K. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat. Anticancer Drug Discov., 2009, 4, 28-35.
61. Montagut, C.; Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett., 2009, 283, 125-134.
62. McCubrey, J.A.; Milella, M.; Tafuri, A.; Martelli, A.M.; Lunghi, P.; Bonati, A.; Cervello, M.; Lee, J.T.; Steelman, L.S. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr. Opin. Investig. Drugs, 2008, 9, 614-630.
63. Halilovic, E.; Solit, D.B. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr. Opin. Pharmacol., 2008, 8, 419-426.
64. Roberts, P.J.; Der, C.J. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 2, 3291-3310.
65. Pratilas, C.A.; Solit, D.B. Therapeutic strategies for targeting BRAF in human cancer. Rev. Recent Clin. Trials, 2007, 2, 121-134.
66. Li, N.; Batt, D.; Warmuth, M. B-Raf kinase inhibitors for cancer treatment. Curr. Opin. Investig. Drugs, 2007, 8, 452-456.
67. Khazak, V.; Astsaturov, I.; Serebriiskii, I.G.; Golemis, E.A. Selective Raf inhibition in cancer therapy. Expert Opin. Ther. Targets, 2007, 11, 1587-1609.
68. Nucera, C.; Goldfarb, M.; Hodin, R.; Parangi, S. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim. Biophys. Acta, 2009, 1795, 152-61.
69. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109.
70. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J. Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov., 2006, 5, 835-844.
71. Smalley, K.S.; Flaherty, K.T. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br. J. Cancer, 2009, 100, 431-435.
72. Zhu, T.; Jiao, Y.; Chen, Y.D.; Wang, X.; Li, H.F.; Zhang, L.Y.; Lu, T. Pharmacophore identification of Raf-1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2346-2350.
73. Thaimattam, R.; Daga, P.; Rajjak, S.A.; Banerjee, R.; Iqbal, J. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies. Bioorg. Med. Chem., 2004, 12, 6415-6425.
74. Liu, Y.; Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol., 2006, 2, 358-364.
75. Bogoyevitch, M.A.; Fairlie, D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today, 2007, 12, 622-633.
76. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9, 28-39.
77. Wong, H.; Belvin, M.; Herter, S.; Hoeflich, K.P.; Murray, L.J. Wong, L.; Choo, E.F. Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl) - 1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy. J. Pharmacol. Exp. Ther., 2009, 329, 360-367.
78. Hoeflich, K.P.; Herter, S.; Tien, J.; Wong, L.; Berry, L.; Chan, J. O'Brien, C.; Modrusan, Z.; Seshagiri, S.; Lackner, M.; Stern, H. Choo, E.; Murray, L.; Friedman, L. S.; Belvin, M. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res., 2009, 69, 3042-3051.
79. Ibrahim, P.N.; Artis, D.R.; Bremer, R.; Habets, G.; Mamo, S. Nespi, M.; Zhang, C.; Zhang, J.Z.; Zhu, Y.L.; Zuckerman, R. West, B.; Suzuki, Y.; Tsai, J.; Hirth, K.P.; Bollag, G.; Spevak, W. Cho, H.; Gillette, S.J.; Wu, G.X.; Zhu, H.Y.; Shi, S.H. Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors. PCT Pat. Appl. WO 2007002325, 2007.
80. Xie, P. Structure based design of potent and specific phosphatidyl-inositol-3-kinase and BRAF inhibitors. Ph.D. United States - Pennsylvania: University of Pennsylvania; 2008.
81. DiPietro, L.V.; Harmange, J.C.; Askew, B.C.; Elbaum, D.; Germain, J.; Habgood, G.J.; Kim, J.L.; Patel, V.F.; Potashman, M. Van der P.S. Fused Azoles such as 2,5-Disubstituted Benzimidazoles, Benzoxazoles and Benzothiazoles. PCT Pat. Appl. WO 04085425, 2004.
82. Renhowe, P.A.; Ramurthy, S.; Amiri, P.; Levine, B.H.; Poon, D.J. Subramanian, S.; Sung, L.; Fantl, W. Substituted Benzazoles and Use Thereof as Raf Kinase Inhibitors. PCT Pat. Appl. WO 03082272, 2003.
83. Amiri, P.; Fantl, W.; Levine, B.H.; Poon, D.J.; Ramurthy, S. Renhowe, P.A.; Subramanian, S.; Sung, L. Substituted Benzazoles and Use Thereof as Inhibitors of Raf Kinase. PCT Pat. Appl. WO 05032548, 2004.
84. Hedge, P.J.; Boyle, F.T. Benzamides as Raf Kinase Inhibitors. PCT Pat. Appl. WO 98022103, 1997.
85. Hall-Jackson, C.A.; Eyers, P.A.; Cohen, P.; Goedert, M.; Boyle, F.T.; Hewitt, N.; Plant, H.; Hedge, P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol., 1999, 6, 559-568.
86. Muddassar, M.; Pasha, F.A.; Yoo, K.H.; Lee, S.H.; Cho, S.J. Doking and quantum mechanics-guided CoMFA analysis of b-RAF in-hibitors. Bull Korean Chem. Soc., 2008, 29, 1499-1505.
87. Fratev, F.; Jonsdottir, S.O.; Mihaylova, E.; Pajeva, I. Molecular Basis of Inactive B-RAF(WT) and B-RAF(V600E) Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study. Mol. Pharm., 2009, 6, 144-157.
88. Smalley, K.S.; Flaherty, K.T. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol., 2009, 5, 775-778.
89. Bikker, J.A.; Brooijmans, N.; Wissner, A.; Mansour, T.S. Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies. J. Med. Chem., 2009, 52, 1493-1509.
90. Emery, C.M.; Vijayendran, K.G.; Zipser, M.C.; Sawyer, A.M. Niu, L.; Kim, J.J.; Hatton, C.; Chopra, R.; Oberholzer, P.A.; Karpova, M.B.; MacConaill, L.E.; Zhang, J.; Gray, N.S.; Sellers, W.R. Dummer, R.; Garraway, L.A. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U.S.A., 2009, 106(48), 20411-20416.